Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 11,405 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: Large B-Cell Lymphoma
Interventions: Glofitamab, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 60
States / cities: Anchorage, Alaska • Anaheim, California • Clovis, California + 49 more

Conditions: Ulcerative Colitis
Interventions: Infliximab 5 mg/kg, Infliximab 10 mg/kg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: Not listed
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 44
States / cities: Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 41 more

Conditions: Alzheimer Disease
Interventions: Donepezil, Vitamin E; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 55 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 63
States / cities: Phoenix, Arizona • Tucson, Arizona • Irvine, California + 53 more

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: alemtuzumab GZ402673; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,062 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 52
States / cities: Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more

Conditions: Heart Failure
Interventions: HM II (HeartMate II LVAD), OMM (Optimal Medical Management); Device · Drug
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 52
States / cities: Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 41 more

Conditions: Post-Traumatic Stress Disorder
Interventions: Sertraline, Cognitive behavioral therapy (CBT); Drug · Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Endometrial Cancer
Interventions: Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 57
States / cities: Little Rock, Arkansas • Duarte, California • La Jolla, California + 50 more

Conditions: Avian Influenza, Influenza Immunisation
Interventions: A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 70 Years
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more

Conditions: Concussion, Brain
Interventions: Pre-game Safety Huddles; Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 11 Years to 14 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Interventions: larotrectinib(Vitrakvi, BAY2757556); Drug
Lead sponsor: Bayer; Industry
Eligibility: Not listed
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 33
States / cities: Los Angeles, California • Newport Beach, California • Palo Alto, California + 28 more

Conditions: Hypertrophic Cardiomyopathy
Interventions: EDG-7500; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 21
States / cities: San Francisco, California • Stanford, California • Atlanta, Georgia + 16 more

Conditions: Neuroblastoma
Interventions: Lorlatinib, Cyclophosphamide, Topotecan, Filgrastim/pegfilgrastim; Drug
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 1 Year to 99 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more

Conditions: HIV Prevention, Pre-exposure Prophylaxis, STI
Interventions: Health service - home-based PrEP monitoring; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 458 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes, Aging
Interventions: Telehealth for Diabetes Self Management, Telehealth for Diabetes Self Management; Behavioral · Other
Lead sponsor: University of Washington; Other
Eligibility: 60 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lung Cancer
Interventions: cisplatin, etoposide, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2010
U.S. locations: 242
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 189 more

Conditions: GERD
Interventions: NDO Full-thickness Plicator; Device
Lead sponsor: NDO Surgical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 6
States / cities: Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 3 more

Conditions: Prostate Cancer
Interventions: Control, Sipuleucel-T; Other · Biological
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2015
U.S. locations: 18
States / cities: Berkeley, California • Laguna Hills, California • Aurora, Colorado + 13 more

Conditions: Pain, Acute
Interventions: Virtual Reality psychological pain reduction; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: IMC-A12, Mitoxantrone, Prednisone, IMC-1121B (ramucirumab); Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: La Jolla, California • New Haven, Connecticut • Boca Raton, Florida + 28 more

Conditions: Chronic Idiopathic Urticaria
Interventions: Placebo, Omalizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 36
States / cities: La Jolla, California • Los Angeles, California • Redwood City, California + 31 more

Conditions: Colitis, Ulcerative
Interventions: Trichuris suis ova (TSO), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 17
States / cities: Palo Alto, California • New Haven, Connecticut • Miami, Florida + 13 more

Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions: Zanubrutinib; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 24
States / cities: Aurora, Colorado • Newark, Delaware • Fort Myers, Florida + 21 more

Conditions: Central Nervous System Neoplasm, Solid Neoplasm
Interventions: Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory Biomarker Analysis, Pharmacological Study, Trebananib; Procedure · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 21
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 16 more

Conditions: Colonic Neoplasms
Interventions: Not listed
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • Urbana, Illinois • Boston, Massachusetts + 8 more

Search by objective public record fields.

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients

Memory Impairment Study (Mild Cognitive Impairment Study)

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management

Comparison of Two Treatments for Post-Traumatic Stress Disorder

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

2017 A/H7N9 IIV Revaccination

One Team: Changing the Culture of Youth Sport With Pregame Safety Huddles

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program

Telehealth for Diabetes Self-Management

Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer

Study of the NDO Endoscopic Plication System For the Treatment of Symptomatic Gastroesophageal Reflux Disease

PROvenge Treatment and Early Cancer Treatment

Water-friendly Virtual Reality and Brief Thermal Pain

A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)

Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors

Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas